FDA approves IntraBio's Aqneursa for ataxia in ataxia-telangiectasia; Alkermes posts Phase 1b ADHD data; Biokin banks $250M ...
ADARx sets terms for a Nasdaq IPO at $15-$17 a share as Treg biotech TRexBio and hypertension player Retension file for their own floats.
Pfizer and Lilly's MFN contracts with HHS show the drugmakers agreed to share revenue from higher overseas prices with the government.
Iambic launched Enchant v3, a 41B parameter AI model, and signed an R&D deal with AbbVie for small molecules in immunology, neuroscience, and oncology.
Novo unveils pipeline-diversification and bolt-on deal plans at its capital markets day, but shares slide 5% as investors ...
FDA briefing documents stay neutral on Grail's Galleri multi-cancer blood test ahead of Wednesday's adcomm vote on safety and benefit.
The merger will combine ITM’s commercial radioisotope manufacturing with Telix’s radiotherapy pipeline. But some deal milestones hinge on a recently rejected drug.
Cue Biopharma's CUE-221 beats Xolair in a Phase 2 chronic hives trial, sending shares up 30% as it eyes a pivotal study.
Welcome back to another edition of Endpoints Weekly! We’ll get to the headlines in just a bit, but be sure to check out the ...
Six UK parliamentary committees ask the National Audit Office to probe the cost of the £1B UK-US pharma deal and its NHS ...
CMS signaled drugmakers joining its Generous Medicaid rebate demo would be exempt from the Globe and Guard Medicare pilots, ...
Gilead expands lenacapavir HIV PrEP access in Latin America; Cloudbreak IPO probed; Sironax gets $125M from Novartis; Circle ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results